April 7, 2003 |
While leading cancer researchers are suggesting that 2 million U.S. women are good candidates for tamoxifen to reduce their risk of breast cancer, some doctors and consumer health advocates are questioning the soundness of that advice. Because the drug is known to raise the risk of uterine cancer, stroke and blood clots, they caution that women should wait to begin such therapy until more is known about the medication's long-term effects.
April 2, 2003 |
Using tamoxifen in hopes of preventing breast cancer would benefit about 2.4 million women despite the drug's serious side effects, federal researchers reported Tuesday. Tamoxifen is a breast cancer treatment that also can cut by almost half a still-healthy woman's risk of developing the disease. Deciding to use it preventively is a difficult choice, however, because tamoxifen can cause uterine cancer and potentially fatal blood clots.
September 24, 2002 |
Barr Laboratories Inc. must delay introducing its version of AstraZeneca's tamoxifen cancer drug, the Food and Drug Administration said. The maker of generic drugs said it would sue the agency. Barr sells tamoxifen through an agreement with AstraZeneca and had hoped to introduce its formula Aug. 20. The FDA ruling would postpone that to February.
July 22, 2002 |
For post-menopausal women with estrogen-sensitive breast cancer, chemotherapy may offer no benefit, and a five-year course after surgery of tamoxifen, which blocks the hormone, may be the only treatment needed, a study shows.
May 20, 2002 |
An expert panel recommended Sunday that doctors stick with tamoxifen as the time-tested treatment for early-stage breast cancer, despite evidence that newer drugs may do a better job of preventing recurrence. The decision affects the care of about 700,000 women in the U.S. who take tamoxifen to prevent their breast cancer from coming back.
December 31, 2001 |
Reducing the risk of recurrent breast cancer in women treated for the disease or keeping the cancer at bay in those who are predisposed have been issues facing doctors for decades. Tamoxifen, prescribed for more than 20 years as a medication to reduce the risk of the disease, is a reliable choice for doctors treating breast cancer patients. And, as a major study three years ago showed, the drug works well stopping cancer before it starts in women at high risk.